Ovarian Cancer: Mutations, Biomarkers, and Treatment with PARP Inhibitors and Immunotherapy – Enduring Webcast

Description

Program Description

---

As the treatment of ovarian cancer (OC) moves further into personalized medicine, the importance of determining the inherited mutations in cancer susceptibility genes has grown. It is becoming routine to test for germline mutations in the BRCA1 and BRCA2 genes, which are responsible for a significant proportion of OC and are established predictive biomarkers of potential benefit from poly ADP ribose polymerase (PARP) inhibitors. The BRCA mutations and HR-deficiency occur in around 50% of OC, leading to increased response and survival after Poly (ADP-ribose) polymerase inhibitors (PARPis) administration. PARPis represent a breakthrough for OC therapy. On the contrary, immune checkpoint inhibitors (ICIs), another breakthrough therapy for many solid tumors, led to modest results in OC without clinical approvals. Therefore, combinations aiming to overcome resistance mechanisms have become of great interest. Recently, PARPis have been evidenced to modulate tumor microenvironment at the molecular and cellular level, potentially enhancing ICIs responsiveness. This represents the rationale for the combined administration of PARPis and ICIs.

Intended Audience

---

Oncologists, obstetrician-gynecologists, pathologists, nurse practitioners, physician assistants, and nurses in diagnosing and treating patients with ovarian cancer.

Commercial Supporter

---

This activity is supported by an educational grant from Merck Sharp & Dohme and AstraZeneca Pharmaceuticals.